STUDIO
Ultimovacs CEO: “Data could put us at the forefront of cancer...
Ultimovacs has announced positive survival data from the phase II NIPU trial assessing the universal cancer vaccine UV1 in malignant mesothelioma. The company’s CEO...
RECOMMENDED READING
Ultimovacs CEO: “Data could put us at the forefront of cancer...
Ultimovacs has announced positive survival data from the phase II NIPU trial assessing the...
Scandions CMO: “Our overall survival data are quite impressive”
Scandion Oncologys läkemedelskandidat SCO-101 utvärderas för närvarande i fas II-studien CORIST för behandling av...